Analyst Update: ISIS Pharmaceuticals, Seadrill, Visa

Analysts adjusted their ratings on ISIS, SDRL, and V

Dec 8, 2014 at 2:04 PM
facebook twitter linkedin


Analysts are weighing in today on drugmaker ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS), oil rig operator Seadrill Ltd (NYSE:SDRL), and credit card giant Visa Inc (NYSE:V). Here's a quick look at today's brokerage notes on ISIS, SDRL, and V.

  • ISIS has jumped 9% this afternoon to trade at $57.51, after a number of brokerage firms responded positively to the company's recent drug trial data. Specifically, Piper Jaffray upped its price target to $81, BMO lifted its target to $75, and Stifel Nicolaus boosted its target to $66 -- with the latter two reiterating the equivalent of a "buy" recommendation. Longer term, shares of ISIS Pharmaceuticals, Inc. have gained more than 43% year-to-date. As such, traders at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) have been buying to open calls over puts at an annual-high rate in recent weeks. ISIS' 10-day call/put volume ratio of 32.98 outstrips all other readings from the past 12 months.

  • SDRL is down nearly 5% at $11.72, following a pair of price-target cuts from Cowen and Company (to $12 from $27) and Credit Suisse (to $15 from $20), with both reaffirming the equivalent of a "hold" opinion. In fact, the stock earlier touched another five-year low of $11.55. Not surprisingly, short sellers have been turning up the heat on Seadrill Ltd. Short interest rose 16.4% during the most recent reporting period, and now accounts for 8.4% of SDRL's total available float.

  • V raced to a record high of $265.63 this morning, and was last seen up 0.2% at $263.87. Sparking the rally was a price-target boost to $299 from $251 at Nomura, which also repeated its "buy" rating. Given Visa Inc's technical tenacity, option players have been upping the bullish ante at a breakneck pace over the last two weeks. The stock's 10-day ISE/CBOE/PHLX call/put volume ratio of 3.50 rests at the top of its annual range. The brokerage crowd is similarly bullish, as V has received 20 "buy" or better recommendations, compared to four "holds" and not a single "sell."
 

Now is the time to join our thriving community of Event Traders who consistently profit from every earnings season. With this discounted subscription opportunity, you'll stay ahead of the curve and seize opportunities others miss. Do not let Q3 earnings season pass you by – subscribe now and supercharge your portfolio with expert insights that turn market reactions into profit-generating opportunities!! Don't waste another second... join us right now before the next trade targeting +200% is released!